非胃原发肿瘤行肿瘤细胞减灭术联合腹腔热灌注化疗时胃切除术的30年结局
该研究基于1991至2024年前瞻性数据库,分析1868例因非胃原发肿瘤接受CRS+HIPEC的患者,其中145例(7.76%)同时行胃切除术。胃切除组患者PCI更高、R2切除比例更高,严重并发症和30天死亡率也更高;多因素分析显示胃切除术本身与总生存无关,而PCI、切除状态、淋巴结、肿瘤分级和原发部位与总生存显著相关。
要点
- 非胃原发肿瘤CRS+HIPEC中约8%需行胃切除术,以阑尾来源最常见。
- 胃切除组PCI更高、R2切除更多,严重并发症和30天死亡率显著高于非胃切除组。
- 胃切除术类型并非总生存的独立影响因素,PCI和切除状态等才是关键预后因素。
核心结论
- 胃切除术本身不是非胃原发肿瘤CRS+HIPEC患者总生存的独立影响因素(多因素分析p=0.18)。
- PCI、切除状态、淋巴结、肿瘤分级和原发部位与总生存显著相关。
研究设计与样本
- 回顾性分析1991至2024年前瞻性数据库,共纳入1868例因非胃原发肿瘤接受CRS+HIPEC的患者。
- 按胃切除范围分层(major 23例、distal 45例、wedge 77例,共145例,占7.76%),并与未行胃切除患者比较结局。
主要发现
- 胃切除组中阑尾来源肿瘤占比最高(major 96%、distal 91%、wedge 68%),非胃切除组为53%。
- 胃切除组中位PCI更高:major 27(7.0)、distal 24(7.0)、wedge 19(10.3),非胃切除组14(9.5),p<0.001。
- R2切除比例在胃切除组更高:major 96%、distal 89%、wedge 60%,非胃切除组45%,p<0.001。
- 严重并发症发生率:major 30%、distal 27%、wedge 19%,非胃切除组12%,p<0.001。
- 30天死亡率:major 17%、distal 11%、wedge 10%,非胃切除组5%,p<0.001;30天再入院和复发无差异。
关键数值与推荐
- 胃切除组与非胃切除组基线人口学无差异。
- 住院时间:major 24(15.2)天、distal 23(25.7)天、wedge 18(22.2)天,非胃切除组12(12.5)天,p<0.001。
临床怎么用
- 对非胃原发肿瘤行CRS+HIPEC时,若需联合胃切除,应充分评估PCI和可切除性,并警惕更高的并发症和死亡率。
- 胃切除术类型本身不决定生存,预后更多取决于PCI、切除彻底性、淋巴结状态、肿瘤分级和原发部位。
局限性
- 为单中心前瞻性数据库的回顾性分析,胃切除组样本量较小(145例)。
- 胃切除组PCI更高、R2切除更多,存在选择偏倚,可能影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival for patients with peritoneal surface malignancy. Completeness of cytoreduction correlates with prognosis. The role of gastrectomy in these patients is not well described. STUDY DESIGN: A total of 1868 patients who underwent CRS+HIPEC for nongastric primary between 1991 and 2024 were analyzed from a prospective database. Patients were stratified by gastrectomy extent and their outcomes compared with no-gastrectomy patients. Continuous variables are presented as mean (SD), categorical variables as N (%), and values considered statistically significant at <0.05. RESULTS: No differences were observed in baseline demographics between the gastrectomy and no-gastrectomy groups. There were 23 major, 45 distal, and 77 wedge gastrectomies (n = 145, 7.76%). Appendiceal was the most common neoplasm in the gastrectomy groups (major: 96%, distal: 91%, wedge: 68%, no gastrectomy: 53%). Gastrectomy patients had higher median peritoneal carcinomatosis index (PCI) (major: 27 [7.0], distal: 24 [7.0], wedge: 19 [10.3], no-gastrectomy: 14 [9.5]; p < 0.001), R2 resection (major: 96%, distal: 89%, wedge: 60%, no-gastrectomy: 45%; p < 0.001), severe complications (major: 30%, distal: 27%, wedge: 19%, no-gastrectomy: 12%; p < 0.001), length of stay (major: 24 [15.2], distal: 23 [25.7], wedge: 18 [22.2], no-gastrectomy: 12 [12.5] days; p < 0.001), and 30-day mortality (major: 17%, distal: 11%, wedge: 10%, no-gastrectomy: 5%; p < 0.001). There was no difference in 30-day readmission or recurrence. On multivariate analysis, gastrectomy was not independently associated with overall survival (p = 0.18). CONCLUSIONS: Approximately 8% of patients who underwent CRS+HIPEC for nongastric primaries underwent gastrectomy. Gastrectomy patients were more likely to have higher PCI and incomplete resections with increased complications and mortality. PCI, resection status, lymph nodes, tumor grade, and primary site, but not gastrectomy type, are significantly associated with overall survival.
引用
- Cos H, Russell G, Perry K, et al. Outcomes for Gastrectomy During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongastric Primaries: 30-Year Experience. J Am Coll Surg. 2025. PMID: 39840852. doi:10.1097/XCS.0000000000001292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。